logo

  • The Company
    The Company
      • Promore Pharma in Brief
      • Vision and Strategy
      • Market
      • Team
      • Board of Directors
  • Projects
    Projects
      • Project Overview
      • PXL01 – Prevention of Post-Surgical Adhesions and Scars
      • LL-37 – Healing of Chronic Wounds
      • Publications
  • Investors
    Investors
      • Promore Pharma on Nasdaq First North Growth Market
        • Certified Adviser
      • The Share
        • Shareholders
        • Warrant Programs
        • Share capital development
      • Financial Reports
      • Press Releases
      • Prospectuses
      • Presentations and Events
      • Calendar
      • Subscribe
  • Corporate Governance
    Corporate Governance
      • Corporate Governance
      • General Meeting
        • General Meetings
      • Nomination Committee
        • Nomination Committees
      • The Board of Directors
        • Board of Directors
      • The Management
        • Management
      • Remunerations and Remuneration Committee
      • Auditor and Audit Committee
      • Articles of Association
      • Certificate of Registration
  • Media
    Media
      • Press Releases
      • Imagebank
      • Subscribe
  • Contact
    Contact
      • Office
      • Investors
      • Media
Svenska
The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • PXL01 – Prevention of Post-Surgical Adhesions and Scars
  • LL-37 – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
    • Certified Adviser
  • The Share
    • Shareholders
    • Warrant Programs
    • Share capital development
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
    • General Meetings
  • Nomination Committee
    • Nomination Committees
  • The Board of Directors
    • Board of Directors
  • The Management
    • Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Media

  • Press Releases
  • Imagebank
  • Subscribe

Contact

Jenni Björnulfson

 Chief Financial Officer (CFO) +46 708 55 38 05

Press Releases

All press releases
  • Regulatory press releases
  • Non-regulatory press releases
2017
  • 2020
  • 2019
  • 2018
  • 2016
  • 2015
  • 2013
  • All years
November 21, 2017

Interim report January – September 2017

November 14, 2017

Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060

October 31, 2017

Promore Pharma Signs Agreement with CRO PCG Clinical Services

October 30, 2017

Promore Pharma Completes Extensive European Collaboration Regarding DPK-060

September 21, 2017

Promore Pharma Signs Manufacturing Agreement with APL

September 12, 2017

Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days

August 30, 2017

Interim report January – June 2017

July 4, 2017

Promore Pharma starts trading on Nasdaq First North on 6 July 2017

June 30, 2017

Promore Pharma awaiting approval from Nasdaq First North in next week

June 26, 2017

New share issue in Promore Pharma raises 76 MSEK ahead of listing on Nasdaq First North

June 7, 2017

Promore Pharma Carries Out a Share Issue Prior to Listing on Nasdaq First North

May 19, 2017

Interim report January – March 2017

May 17, 2017

Promore Pharma AB files phase III clinical trial application in India

April 26, 2017

Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO

The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • PXL01 – Prevention of Post-Surgical Adhesions and Scars
  • LL-37 – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
  • The Share
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
  • Nomination Committee
  • The Board of Directors
  • The Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Promore Pharma AB. Address: Fogdevreten 2, SE-171 65 Solna, Sweden. Phone: +46 8 124 548 59. E-mail: info@promorepharma.com. Registration number: 556639-6809.

  • Personal data
  • About cookies

Welcome to Promore Pharma AB’s website. In order to optimize your use of our website we use cookies. A cookie is a text file stored on your computer. If you want more information about what a cookie is, what the purpose of the cookie is and how you can block or delete cookies, please read the our cookie guidelines “About cookies”. By continuing, you agree to our use of cookies.

Yes, I accept